載入...
An appraisal of drug development timelines in the Era of precision oncology
The effects of incorporating a biomarker-based (personalized or precision) selection strategy on drug development timelines for new oncology drugs merit investigation. Here we accessed documents from the Food and Drug Administration (FDA) database for anticancer agents approved between 09/1998 and 0...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5288167/ https://ncbi.nlm.nih.gov/pubmed/27419632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10588 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|